e-learning
resources
Milan 2017
Sunday, 10.09.2017
Pleural disease and mesothelioma: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Prognostic and therapeutic markers of malignant pleural effusion – The PROMISE study
I. Psallidas (Oxford, United Kingdom)
Source:
International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside
Session:
Pleural disease and mesothelioma: from the bench to the bedside
Session type:
Oral Presentation
Number:
292
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Psallidas (Oxford, United Kingdom). Late Breaking Abstract - Prognostic and therapeutic markers of malignant pleural effusion – The PROMISE study. 292
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of solitary fibrous tumours of the pleura: a systematic review and meta-analysis
Utility of pleural fluid for predictive marker testing in malignant pleural effusion
Massive pleural effusion presented with a very rare multitude of complication
Related content which might interest you:
Biological markers of successful pleurodesis for malignant pleural effusion
Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside
Year: 2016
Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions
Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Year: 2015
Predictive value of pro-inflammatory cytokine and pro-angiogenic factor in differentiating malignant from benign exudative effusion
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Predictive parameters of survival in malignant pleural effusion
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015
Prognostic characteristics of malignant pleural mesothelioma
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Idiopathic pleural effusions (IPE) and predictive prognosis
Source: International Congress 2015 – Interventional pulmonology for pleural diseases
Year: 2015
Haematologic parameters and their prognostic impact in malignant pleural mesothelioma
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Contribution of PIPE Score on prognostic evaluation of idiopathic pleural effusions (IPE)
Source: International Congress 2016 – Pleural diseases
Year: 2016
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma
Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Year: 2013
Prognostic significance of pleural tumour burden in patients with malignant pleural effusions
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
Prognostic factors in diffuse malignant pleural mesothelioma
Source: Eur Respir J 2003; 22: Suppl. 45, 62s
Year: 2003
Prognostic factors in patients with malignant pleural effusion undergoing thoracoscopy
Source: Annual Congress 2011 - From outside to inside: access to the pleura
Year: 2011
Prognostic factors in diffuse malignant pleural mesothelioma
Source: Eur Respir J 2007; 30: Suppl. 51, 755s
Year: 2007
Hemorrhagic malignant pleural effusion: Diagnosis, survival rate, and response to talc pleurodesis
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Pleural ultrasonic elastography in the diagnosis of malignant pleural effusion
Source: International Congress 2016 – Malignant pleural disease: diagnosis and management
Year: 2016
Lent score validation on patients with malignant pleural effusion
Source: International Congress 2016 – Malignant pleural disease: diagnosis and management
Year: 2016
Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Role of Dr-70 immunoassay in suspected malignant pleural effusion
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
Tunneled indwelling pleural catheter (TPC) in recurrent malignant pleural effusions: A retrospective study of 230 patients
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept